DGAP-News: Elanix Biotechnologies AG

PRESS RELEASE

Elanix Biotechnologies Subsidiary Signs Wholesale & Logistics Agreement in Europe to Support Expanding Commercialization of GYNrepair^(R)

Nyon, Switzerland and Berlin, Germany, September 20, 2017 -- Elanix Biotechnologies AG (FSE: ELN), a developer of tissue regeneration products, announced today that Repair-A, its wholly owned subsidiary, has signed a logistics and wholesale agreement with Ivry Lab, covering GYNrepair^(R), Elanix's topical women's health cream. The agreement provides for the logistical infrastructure to make GYNrepair available for rapid distribution to pharmacies throughout Europe.

"As commercialization efforts of GYNrepair continue to ramp up, this agreement establishes the infrastructure foundation to ensure supplies are readily available and dispatched across Europe from controlled storage facilities," stated Tomas Svoboda, CEO of Elanix. "This important B2B component of our strategy complements our B2C, direct to consumer, agreement with Apraxon rolled out earlier this year."

Ivry Lab, based outside Paris, is part of the PHOENIX Group of companies that serve more than 3,500 pharmacies in France and leader of pharmaceutical wholesale in 12 countries in Europe. Ivry Lab has a proven technical competence and provides services in the daily management and operations of healthcare logistics outsourcing.

Repair-A SA is dedicated to the development and marketing of progenitor cell based bioactive CFPC^(R) creams. Since its founding in 2007, Repair-A has marketed two bioactive CFPC creams, based on animal progenitor cell technology that originated from Professor Lee-Ann Laurent Applegate's research in Switzerland. Elanix Biotechnologies acquired Repair-A in September 2016 and is in the process of scaling up marketing of the products and commercialization worldwide.

Elanix Biotechnologies AG (Frankfurt: ELN) develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working human cell banks with vast quantities of cells.

Elanix is headquartered in Nyon, Switzerland with offices in Potsdam, Germany, and listed on the Frankfurt stock exchange under the symbol ELN. For more information and updates, visit www.elanixbiotechnologies.com.

Press Contacts:

Disclaimer / Forward-looking statements:

This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.